137 related articles for article (PubMed ID: 17438403)
1. Carvedilol reduces elevated B-type natriuretic peptide in dialyzed patients without heart failure: cardioprotective effect of the beta-blocker.
Kojima M; Sato K; Kimura G; Ueda R; Dohi Y
J Cardiovasc Pharmacol; 2007 Apr; 49(4):191-6. PubMed ID: 17438403
[TBL] [Abstract][Full Text] [Related]
2. Effect of Carvedilol on Serum Heart-type Fatty Acid-binding Protein, Brain Natriuretic Peptide, and Cardiac Function in Patients With Chronic Heart Failure.
Sun YP; Wei CP; Ma SC; Zhang YF; Qiao LY; Li DH; Shan RB
J Cardiovasc Pharmacol; 2015 May; 65(5):480-4. PubMed ID: 25945865
[TBL] [Abstract][Full Text] [Related]
3. Effects of carvedilol on plasma B-type natriuretic peptide concentration and symptoms in patients with heart failure and preserved ejection fraction.
Takeda Y; Fukutomi T; Suzuki S; Yamamoto K; Ogata M; Kondo H; Sugiura M; Shigeyama J; Itoh M
Am J Cardiol; 2004 Aug; 94(4):448-53. PubMed ID: 15325927
[TBL] [Abstract][Full Text] [Related]
4. N-terminal prohormone brain natriuretic peptide plasma levels in heart failure are affected both directly and indirectly by carvedilol.
Kallistratos MS; Dritsas A; Laoutaris ID; Cokkinos DV
Angiology; 2008; 59(3):323-8. PubMed ID: 18388105
[TBL] [Abstract][Full Text] [Related]
5. Impact of initiating carvedilol before angiotensin-converting enzyme inhibitor therapy on cardiac function in newly diagnosed heart failure.
Sliwa K; Norton GR; Kone N; Candy G; Kachope J; Woodiwiss AJ; Libhaber C; Sareli P; Essop R
J Am Coll Cardiol; 2004 Nov; 44(9):1825-30. PubMed ID: 15519014
[TBL] [Abstract][Full Text] [Related]
6. Serum biomarkers and clinical outcomes in heart failure patients treated de novo with carvedilol.
Nessler J; Nessler B; Golebiowska-Wiatrak R; Palka I; Gackowski A; Kitlinski M; Melander O; Fedorowski A
Cardiol J; 2013; 20(2):144-51. PubMed ID: 23558872
[TBL] [Abstract][Full Text] [Related]
7. Concentration of BNP, endothelin 1, pro-inflammatory cytokines (TNF-alpha, IL-6) and exercise capacity in patients with heart failure treated with carvedilol.
Nessler J; Nessler B; Kitliński M; Gackowski A; Piwowarska W; Stepniewski M
Kardiol Pol; 2008 Feb; 66(2):144-51; discussion 152-3. PubMed ID: 18344152
[TBL] [Abstract][Full Text] [Related]
8. Increased low-grade inflammation is associated with lack of functional response to carvedilol in patients with systolic heart failure.
Fragasso G; Spoladore R; Maranta F; Corti A; Lattuada G; Colombo B; Locatelli M; Salerno A; Calori G; Briceno L; Alfieri AB; Perseghin G; Margonato A
J Cardiovasc Med (Hagerstown); 2013 Jan; 14(1):49-56. PubMed ID: 23018486
[TBL] [Abstract][Full Text] [Related]
9. Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial.
Jabbour A; Macdonald PS; Keogh AM; Kotlyar E; Mellemkjaer S; Coleman CF; Elsik M; Krum H; Hayward CS
J Am Coll Cardiol; 2010 Apr; 55(17):1780-7. PubMed ID: 20413026
[TBL] [Abstract][Full Text] [Related]
10. Prognostic importance of plasma NT-pro BNP in chronic heart failure in patients treated with a beta-blocker: results from the Carvedilol Or Metoprolol European Trial (COMET) trial.
Olsson LG; Swedberg K; Cleland JG; Spark PA; Komajda M; Metra M; Torp-Pedersen C; Remme WJ; Scherhag A; Poole-Wilson P;
Eur J Heart Fail; 2007 Aug; 9(8):795-801. PubMed ID: 17693380
[TBL] [Abstract][Full Text] [Related]
11. Carvedilol therapy is associated with a sustained decline in brain natriuretic peptide levels in patients with congestive heart failure.
Frantz RP; Olson LJ; Grill D; Moualla SK; Nelson SM; Nobrega TP; Hanna RD; Backes RJ; Mookadam F; Heublein D; Bailey KR; Burnett JC
Am Heart J; 2005 Mar; 149(3):541-7. PubMed ID: 15864245
[TBL] [Abstract][Full Text] [Related]
12. Restrictive left ventricular filling pattern and its effect on the clinical course of systolic heart failure in patients receiving carvedilol.
Nessler J; Nessler B; Kitliński M; Stepniewski M; Piwowarska W
Cardiol J; 2008; 15(4):329-37. PubMed ID: 18698541
[TBL] [Abstract][Full Text] [Related]
13. Low-dose carvedilol improves left ventricular function and reduces cardiovascular hospitalization in Japanese patients with chronic heart failure: the Multicenter Carvedilol Heart Failure Dose Assessment (MUCHA) trial.
Hori M; Sasayama S; Kitabatake A; Toyo-oka T; Handa S; Yokoyama M; Matsuzaki M; Takeshita A; Origasa H; Matsui K; Hosoda S;
Am Heart J; 2004 Feb; 147(2):324-30. PubMed ID: 14760332
[TBL] [Abstract][Full Text] [Related]
14. Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study.
Olsen SL; Gilbert EM; Renlund DG; Taylor DO; Yanowitz FD; Bristow MR
J Am Coll Cardiol; 1995 May; 25(6):1225-31. PubMed ID: 7722114
[TBL] [Abstract][Full Text] [Related]
15. Effects of carvedilol, a vasodilator-beta-blocker, in patients with congestive heart failure due to ischemic heart disease. Australia-New Zealand Heart Failure Research Collaborative Group.
Circulation; 1995 Jul; 92(2):212-8. PubMed ID: 7600653
[TBL] [Abstract][Full Text] [Related]
16. BNP levels predict outcome in pediatric heart failure patients: post hoc analysis of the Pediatric Carvedilol Trial.
Auerbach SR; Richmond ME; Lamour JM; Blume ED; Addonizio LJ; Shaddy RE; Mahony L; Pahl E; Hsu DT
Circ Heart Fail; 2010 Sep; 3(5):606-11. PubMed ID: 20573993
[TBL] [Abstract][Full Text] [Related]
17. [Preliminary study on the effect of carvedilol on children with primary endocardial fibroelastosis].
Li R; Yi QJ; Qian YR; Liu XY; Zhong JR; Bai YH; Mi Q; Li XL
Zhonghua Er Ke Za Zhi; 2008 Sep; 46(9):684-7. PubMed ID: 19099859
[TBL] [Abstract][Full Text] [Related]
18. Effects of beta-blocker therapy on high sensitivity c-reactive protein, oxidative stress, and cardiac function in patients with congestive heart failure.
Nagatomo Y; Yoshikawa T; Kohno T; Yoshizawa A; Anzai T; Meguro T; Satoh T; Ogawa S
J Card Fail; 2007 Jun; 13(5):365-71. PubMed ID: 17602983
[TBL] [Abstract][Full Text] [Related]
19. The effect of carvedilol on B-type natriuretic peptide and cardiac function in patients with heart failure and persistent atrial fibrillation.
Khand AU; Chew PG; Douglas H; Jones J; Jan A; Cleland JG
Cardiology; 2015; 130(3):153-8. PubMed ID: 25660493
[TBL] [Abstract][Full Text] [Related]
20. Brain natriuretic peptide response is heterogeneous during beta-blocker therapy for congestive heart failure.
Yoshizawa A; Yoshikawa T; Nakamura I; Satoh T; Moritani K; Suzuki M; Baba A; Iwanaga S; Mitamura H; Ogawa S
J Card Fail; 2004 Aug; 10(4):310-5. PubMed ID: 15309697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]